Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Quality of life studies and genito-urinary tumors
Autore:
Bertetto, O; Bracarda, S; Tamburini, M; Cortesi, E;
Indirizzi:
Univ Roma La Sapienza, Policlin Umberto I, Dept Expt Med & Pathol, I-00161Rome, Italy Univ Roma La Sapienza Rome Italy I-00161 ed & Pathol, I-00161Rome, Italy Le Molinette Hosp, Div Med Oncol, Turin, Italy Le Molinette Hosp Turin Italy linette Hosp, Div Med Oncol, Turin, Italy Policlin Hosp, Div Med Oncol, Perugia, Italy Policlin Hosp Perugia Italy oliclin Hosp, Div Med Oncol, Perugia, Italy Natl Tumor Inst, Psychol Res Div, Milan, Italy Natl Tumor Inst Milan Italy l Tumor Inst, Psychol Res Div, Milan, Italy
Titolo Testata:
ANNALS OF ONCOLOGY
, volume: 12, anno: 2001, supplemento:, 3
pagine: S43 - S48
SICI:
0923-7534(2001)12:<S43:QOLSAG>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOCALIZED PROSTATE-CANCER; INVASIVE BLADDER-CANCER; TRIAL-SPECIFIC MODULE; RENAL-CELL CARCINOMA; OF-LIFE; RADICAL PROSTATECTOMY; RADIATION-THERAPY; FUNCTIONAL ASSESSMENT; INSTRUMENT PROSQOLI; TESTICULAR CANCER;
Keywords:
genito-urinary tumors; quality of life;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Cortesi, E Univ Roma La Sapienza, Policlin Umberto I, Dept Expt Med & Pathol, Piazzale Aldo Moro 5, I-00161 Rome, Italy Univ Roma La Sapienza Piazzale Aldo Moro 5 Rome Italy I-00161
Citazione:
O. Bertetto et al., "Quality of life studies and genito-urinary tumors", ANN ONCOL, 12, 2001, pp. S43-S48

Abstract

Background: Genitourinary (GU) tumors represent a large proportion of solid cancers (1 of 4) and a wide variety of natural histories, based on various prognostic factors and resulting in different treatment options and end points. In some cases, for the same stage of disease, different treatment strategies do not impact differently on overall survival (OS): surgery vs. radiation, or radical vs. conservative multidisciplinary approach, adjuvant or neoadjuvant, chemotherapy vs. BSC. Quality of life (QoL) is considered a reasonable end point when differences in OS do not seem to be striking. Design: A review of the literature on different disease stages was undertaken to show where and when QoL was used as the end point of treatment efficacy. Results: Very few studies have been performed in prostate, bladder and testicular cancer to show the impact of different treatment approaches on QoL. Although these studies might be considered as non-conclusive, some data may allow a better choice for the patients. Conclusions: QoL as the principal end point has not been used in clinical trials of GU tumors comparing different treatment approaches. This makes the choice between treatments offering similar survival but different toxicity patterns, body and behavioral consequences more difficult. We suggest that future prospective randomized studies should be planned taking into account the QoL as the main end point.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 09:52:03